Clinical studies of frequency domain optical coherence tomography in the coronary arteries: The first 200 patients

Progress in Biomedical Optics and Imaging - Proceedings of SPIE

Volumn 7548, Issue , 2010, Pages

  Petersen, Christopher ^a   Adler, Desmond ^a   Schmitt, Joseph ^a  

^a LightLab Imaging Inc   (United States)

Author keywords

Catheter; FD OCT; Interventional Cardiology; Optical Coherence Tomography; Stent

Indexed keywords

3D IMAGING; CLINICAL STUDY; COMMERCIAL SYSTEMS; CORONARY ARTERIES; CORONARY STENTS; FD-OCT; FRAME RATE; FREQUENCY DOMAIN OPTICAL COHERENCE TOMOGRAPHY; HIGH RESOLUTION; HUMAN CORONARY ARTERIES; IN-VIVO IMAGING; INTERVENTIONAL; INTERVENTIONAL CARDIOLOGY; OPTICAL COHERENCE TOMOGRAPHY; SIDE BRANCHES; STENT; STENT GEOMETRY; STENTING; SWEPT LASERS; THREE-DIMENSIONAL (3D); THROMBUS FORMATION; VASCULAR STRUCTURES; VESSEL DIAMETER;

CARDIOLOGY; CATHETERS; COHERENT LIGHT; FREQUENCY DOMAIN ANALYSIS; HEART; THREE DIMENSIONAL; TOMOGRAPHY;

FINITE DIFFERENCE METHOD;

EID: 77952874016     PISSN: 16057422     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.842448     Document Type: Conference Paper

References (15)

1. Ioannis Iakovou, MD; Thomas Schmidt, MD; Erminio Bonizzoni, PhD; Lei Ge, MD; Giuseppe M. Sangiorgi, MD; Goran Stankovic, MD; Flavio Airoldi, MD; Alaide Chieffo, MD; Matteo Montorfano, MD; Mauro Carlino, MD; Iassen Michev, MD; Nicola Corvaja, MD; Carlo Briguori, MD; Ulrich Gerckens, MD; Eberhard Grube, MD; Antonio Colombo, MD. "Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents", JAMA 2005;293:2126-2130.
2. Gonzalo, Nieves. "Incomplete Stent Apposition and Delayed Tissue Coverage are more frequent in DES implanted during primary PCI for ST-Elevation Myocardial Infarction than in drug-eluting stents implanted for Stable and Unstable angina: Insights from OCT", Oral Abstract, Trans Catheter Therapeutics Conference, San Francisco, USA, 2009.
3. Lakshmana K. Pendyala, Xinhua Yin, Jinsheng Li, Jack P. Chen, Nicolas Chronos and Dongming Hou."The First-Generation Drug-Eluting Stents and Coronary Endothelial Dysfunction" JACC: Cardiovascular Interventions, Volume 2, Issue 12, December 2009, Pages 1169-1177
4. Diener H C, Bogousslavsky J, Brass LM, et al. (2004). "Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial'. Lancet 364 (9431): 331-7. doi: 10.1016/S0140-6736(04)16721-4. PMID 15276392.
5. Savi, P; Zachayus JL, Delesque-Touchard N et al. (July 2006). "The active metabolite of Clopidogrel disrupts P2Y 12 receptor oligomers and partitions them out of lipid rafts". Proceedings of the National Academy of Sciences of the USA 103 (29): 11069 11074. doi:10.1073/pnas.0510446103. PMID 16835302.
6. Kim, Jung-Sun, Jang, Ik-Kyung , Fan, Chunyu, et al. "Evaluation in 3 Months Duration of Neointimal Coverage After Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography: The ENDEAVOR OCT Trial " JACC: Cardiovascular Interventions, Volume 2, Issue 12, December 2009, Pages 1240-1247
7. Philip Moore, Peter Barlis, Jonathan Spiro, Gopal Ghimire, Michael Roughton, Carlo Di Mario, William Wallis, Charles Ilsley, Andrew Mitchell, Mark Mason, Rajesh Kharbanda, Peter Vincent, Spencer Sherwin and Miles Dalby. "A Randomized Optical Coherence Tomography Study of Coronary Stent Strut Coverage and Luminal Protrusion With Rapamycin-Eluting Stents", JACC: Cardiovascular Interventions, Volume 2, Issue 5, May 2009, Pages 437-444
8. Granada, Juan. "OCT in the evaluation of vascular healing following stent implantation", Oral Abstract, Trans Catheter Therapeutics Conference, San Francisco, USA, 2009
9. Akira Murata*, David Wallace-Bradley, Armando Tellez, Carlos Alviar, Michael Aboodi, Alexander Sheehy, Leslie Coleman, Laura Perkins, Gaku Nakazawa, Gary Mintz, Greg L. Kaluza, Renu Virmani, Juan F. Granada.. "Accuracy of Optical Coherence Tomography in the Evaluation of Neointimal Coverage After Stent Implantation," J Am Coll Cardiol 1mg, 2010; 3:76-84.
10. Coronary Drug-Eluting Stents Nonclinical and Clinical Studies Companion Document, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health (CDRH), Center for Drug Evaluation and Research (CDER), March 2008.
11. Castagna MT, Mintz GS, Leiboff BO, et al. The contribution of "mechanical" problems to in-stent restenosis: An intravascular ultrasonographic analysis of 1090 consecutive in-stent restenosis lesions. Am Heart J 2001; 142: 970 974.
12. Serruys, Patrick W ,Ormiston, John A, Onuma, Yoshinobu, Regar,Evelyn, Gonzalo, Nieves, Garcia-Garcia, Hector M, et al, "A Bioabsorbable Everolimus-eluting Coronary Stent System (ABSORB): 2-year outcomes and results from multiple imaging methods", The Lancet, Volume 373, Issue 9667, Pages 897-910, 14 March 2009.
13. Rossi S, editor. [Australian Medicines Handbook 2006]. Adelaide. ISBN 0-9757919-2-3
14. Kandzari, David E, Angiolillo, Dominick J, Price, Matthew J. and Teirstein, Paul S. "Identifying the Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Revascularization JACC: Cardiovascular Interventions", Volume 2, Issue 12, December 2009, Pages 1279-1285
15. Sonoda S, Morino Y, Ako J, et al.; SIRIUS Investigators. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: Serial intravascular ultrasound analysis from the SIRIUS trial. J Am Coll Cardiol 2004; 43: 1959 1963.